The link between diabetes and atrial fibrillation: cause or correlation? by Sun, Yihong & Hu, Dayi
10  Journal of Cardiovascular Disease Research Vol 1 / No 1   |  Available Online : www.jcdronline.org
Journal of Cardiovascular Disease Research  OPEN ACCESS
ISSN : 0975-3583   © 2009 EManuscript 
The link between diabetes and atrial fibrillation:  
cause or correlation?
Yihong Sun, MD,  Dayi Hu, MD, FACC
Heart Centre, Peking University People’s Hospital, China yihongsun72@163.com
Atrial fibrillation (AF) is the most common form of arrhythmia 
in the world.  As the population ages, it is estimated that the 
prevalence of AF will increase by 2.5 fold in the next 50 years.1 
At the same time, diabetes has become a pandemic disease in the 
western world as well as in developing countries. Independent 
risk factors for chronic AF include hypertension, heart failure, 
valvular heart disease and cardiomyopathy. The development 
of AF is likely to be multifactorial and the mechanism is elusive, 
while there is emerging evidence on the correlation between 
AF and diabetes mellitus (DM). DM and AF share common 
antecedents such as hypertension, atherosclerosis and obesity. 
Population-based studies suggested that DM is an independent 
risk factor for atrial fibrillation.2 Both DM and AF are marked 
predictor for stroke and mortality. The causal relation between 
DM and AF is still debatable and will be discussed.
DM as risk factor for AF
DM  is  one  of  the  most  common  concomitant  diseases  in 
patients  with  AF.3  In  a  survey  of  hospitalized  patient,  AF 
occurred in 14.9% of DM patients vs 10.3% in control group 
with hypertension but no DM.4 DM has been cited as the risk 
factor for AF for decades. In the early 1990s, the Framingham 
study indicated DM to be an independent risk factor for AF with 
OR of 1.4 for men and 1.6 for women after 38 years follow-
up.2 In the analysis of 41436 residents in Japan, the prevalence 
of DM  in AF patients is higher than in controls (20% vs 12%). 
The  multivariate  analysis  showed  that  DM  is  independently 
associated with AF (OR, 1.46).5 In the cross sectional survey in 
mainland China, the prevalence of AF in participants with self 
reported DM is higher than those without known DM (1.29% 
vs 0.88%) after adjustment for age and sex.6 However, in the 
development of risk score for AF, DM was not a significant 
predictor of AF in the Framingham cohort.7 Data of China 
survey showed that DM is not an independent risk factors for 
AF in the multivariate model.6
In  the  observational  cohort  study  of  DM  registry,  the 
incidence of AF in diabetic patients was much higher than in 
controls (9.1% vs 6.6%) over a mean follow-up period of of 7.2 
years. After adjustment for other risk factors, DM was associated 
with a 26% increased risk of AF among women (HR, 1.26), 
but not a statistically significant factor among men.5 In patients 
with hypertension, DM is not an independent predictor for 
new onset AF based on the post hoc analysis from ALLHAT 
(Antihypertensive  and  lipid-Lowering  treatment  to  prevent 
heart  attack  trial).9  However,  an  retrospective  analysis  of 
VALUE (Valsartan antihypertensive long-term use evaluation) 
study showed hypertensive patients with new onset DM had a 
significantly higher event rate of new onset AF compared with 
those without DM (5.4% vs 3.8%, HR=1.49) even adjusted for 
body mass index.10
Mechanism of the DM related AF
The link between DM and AF in epidemiology needs to be 
confirmed  in  large,  prospective,  long  term  study,  although 
there  were  evidences  showing  the  underlying  biological 
interlink. Studies have indicated that inflammation might play 
a role in the generation, maintenance, and perpetuation of 
AF, although the mechanism of AF is still elusive. In atrial 
biopsies of patients with lone AF, there were increased CRP 
and IL-6and marked inflammatory infiltrates.11–12 CRP was 
two-fold higher in AF patients compared with control group 
without atrial arrhythmia. It also has been demonstrated that 
inflammatory response may underlie the pathologic processes 
of DM.
Glucose  and  insulin  disturbance  can  directly  affect  the 
myocardium  in  atrium  and  ventricle,  leading  to  AF.  Left 
ventricular (LV) hypertrophy has been associated with DM and 
abnormal glucose tolerance in several epidemiology studies. LV 
hypertrophy is a significant risk factor for AF. Analysis of the 
Framingham study subjects showed that LV mass increased 
with the worsening of glucose tolerance and the trend was 
more striking in women than in man. There were also close 
relationship between insulin resistance and LV mass, as well as 
LV wall thickness, in women both with normal and abnormal 
glucose  tolerance.13  Prospective  data  from  large  population 
based studies has established the relationship between LA size 
and risk of developing AF. In the same study, LV size also 
increased with glucose tolerance and insulin resistance in both 
sexes, but this relation was largely accounted for by obesity. The 
association between AF and DM in relation to body size needs 
further investigation.
Several  observations  suggest  that  the  automatic  nerve 
system plays an important role in both the initiation and/
or the maintenance of AF in humans. In most patients with 
organic heart diseases, the paroxysmal AF episodes appear 
more  sympathetically  dependent.  In  the  animal  model  of 
DM,  the  occurrence  of  AF  was  enhanced  by  adrenergic 
activation  in  diabetic  heart,  in  which  the  sympathetic 
innervations was evident.14–15The intra –atrial conduction 
delay  and  fibrotic  deposition  in  atria  play  a  major  role  in 
producing atrial tachyarrhythmia in diabetes animal model. 
The heterogeneous increase in sympathetic innervations was 
proved to be associated with the promotion of AF in several 
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Summary
In conclusion, the association between AF and DM has been 
proved both in epidemiology and experimental studies. The 
causal links need to be verified in large cohort study. A recent 
report from NIH stated that AF prevention has received less 
attention than treatment and there were great knowledge gaps 
in the understanding of risk factors of AF.16 One important 
research  area  may  be  the  impact  of  DM  on  the  incidence, 
recurrence and progression of AF.
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